{"id":2634,"date":"2019-03-01T12:00:00","date_gmt":"2019-03-01T11:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/neues-zum-vorhofflimmern"},"modified":"2019-03-01T12:00:00","modified_gmt":"2019-03-01T11:00:00","slug":"neues-zum-vorhofflimmern","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/neues-zum-vorhofflimmern","title":{"rendered":"Neues zum Vorhofflimmern"},"content":{"rendered":"<p>Zusammenfassung: Ein Update der US-amerikanischen Leitlinien zur Behandlung von Vorhofflimmern empfiehlt nun, wie die europ\u00e4ischen Leitlinien auch, an erster Stelle die direkten oralen Antikoagulanzien (DOAK) vor den Vitamin-K-Antagonisten, au\u00dfer bei Patienten mit moderater bis schwerer Mitralstenose, mechanischen Herzklappen und terminaler Niereninsuffizienz. Weibliches Geschlecht wird beim CHA2DS2-VASc-Score von einem eigenst\u00e4ndigen Risikofaktor zu einem Risk-Modifier herabgestuft. Frauen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Ein Update der US-amerikanischen Leitlinien zur Behandlung von Vorhofflimmern empfiehlt nun, wie die europ\u00e4ischen Leitlinien auch, an erster Stelle die direkten oralen Antikoagulanzien (DOAK) vor den Vitamin-K-Antagonisten, au\u00dfer bei Patienten mit moderater bis schwerer Mitralstenose, mechanischen Herzklappen und terminaler Niereninsuffizienz. Weibliches Geschlecht wird beim CHA2DS2-VASc-Score von einem eigenst\u00e4ndigen Risikofaktor zu einem Risk-Modifier herabgestuft. Frauen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[185,1426,5190,137,1322,60,3124,4152,1314,1312,2068,5189,187,68,3253,3314,3315,5192,5191,1328,1327,138,3247,183,170,56,54,181,5188,136],"class_list":["post-2634","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-alkohol","tag-andexanet-alfa","tag-antikoagulanzien","tag-apixaban","tag-apoplektischer-insult","tag-bridging","tag-cha2ds2-vasc-score","tag-direkte-orale-antikoagulanzien","tag-doak","tag-edoxaban","tag-engage-timi-48-studie","tag-herzrhythmusstoerungen","tag-hirninfarkt","tag-idarucizumab","tag-mitralinsuffizienz","tag-mitralklappen-insuffizienz","tag-mitralklappen-stenose","tag-mitralstenose","tag-neue-orale-antikoagulanzien","tag-noak","tag-phenprocoumon","tag-re-verse-ad-studie","tag-rhythmusstoerungen","tag-schilddruese","tag-schlaganfall","tag-thromboembolie","tag-vorhofflimmern","tag-vorhofohr","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2634"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2634\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}